In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 361 to 370 of 392

TitleTypeExpected publication date
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891Technology appraisal guidanceTBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidanceTBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Technology appraisal guidanceTBC
Type 2 diabetes in adults: management (medicines update)NICE guideline
Ublituximab for treating relapsing multiple sclerosis [ID6350]Technology appraisal guidanceTBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Technology appraisal guidanceTBC
Urinary Tract Infection (recurrent): antimicrobial prescribingNICE guideline
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All